Literature DB >> 15042552

Intravascular embolization therapy in a patient with an enlarged polycystic liver.

Yoshifumi Ubara1, Ryouji Takei, Jyunichi Hoshino, Tetsuo Tagami, Naoki Sawa, Masafumi Yokota, Hideyuki Katori, Fumi Takemoto, Shigeko Hara, Kenmei Takaichi.   

Abstract

Because the kidneys in patients with autosomal dominant polycystic kidney disease (ADPKD) are usually supplied by well-developed arteries, the authors attempted renal contraction therapy in such patients with renal transcatheter arterial embolization (TAE) using intravascular coils. In most patients with marked nephromegaly, renal TAE was effective. However, in patients with marked hepatomegaly without significant nephromegaly, renal TAE was not effective, and hepatic treatment was always required. In June 2001, the authors obtained approval for a new treatment,"TAE for enlarged polycystic liver," from an ethics committee discussing new treatment at their hospital. A 56-year-old man undergoing hemodialysis for 2 months was referred to the authors' institute with the complaint of severe abdominal distension and loss of appetite in March 2001. Most of the liver (about 90%) had been replaced by multiple cysts, and near-intact hepatic parenchyma was quite scarce. The kidneys were quite small compared with the liver. Angiography results showed that almost all hepatic arterial branches were well developed, although most of the portal vein was obstructed, and only the left medial portal vein was spared; the former corresponded to the hepatic region replaced by multiple cysts and the latter to the preserved intact hepatic parenchyma. The target of TAE was the hepatic arterial branches of the former. Microcoils were used as embolization material. Two years after TAE, abdominal distension has markedly decreased because of decrease in liver size (to 54% of the previous value), and muscle and fat volume in the thoracic region have increased owing to improvement of appetite. Ascites became obscure. Nutrition and activities of daily living have improved. Hepatic TAE may be an option for treatment of patients in poor condition with symptomatic polycystic liver.

Entities:  

Mesh:

Year:  2004        PMID: 15042552     DOI: 10.1053/j.ajkd.2003.12.035

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

Review 1.  Isolated polycystic liver disease.

Authors:  Qi Qian
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

2.  The renal cyst infection caused by Salmonella enteritidis in a patient with autosomal dominant polycystic kidney disease: how did this pathogen come into the renal cysts?

Authors:  Yoshiki Tsuchiya; Yoshifumi Ubara; Tatsuya Suwabe; Junichi Hoshino; Keiichi Sumida; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Noriko Hayami; Yuji Marui; Naoki Sawa; Fumi Takemoto; Kenmei Takaichi
Journal:  Clin Exp Nephrol       Date:  2010-12-04       Impact factor: 2.801

Review 3.  Diagnosis and management of polycystic liver disease.

Authors:  Tom J G Gevers; Joost P H Drenth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

4.  Survival after arterial embolization therapy in patients with polycystic kidney and liver disease.

Authors:  Junichi Hoshino; Tatsuya Suwabe; Noriko Hayami; Keiichi Sumida; Koki Mise; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Naoki Sawa; Ryoji Takei; Kenmei Takaichi; Yoshifumi Ubara
Journal:  J Nephrol       Date:  2014-09-18       Impact factor: 3.902

5.  Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up.

Authors:  Jin-Long Zhang; Kai Yuan; Mao-Qiang Wang; Jie-Yu Yan; Hai-Nan Xin; Yan Wang; Feng-Yong Liu; Yan-Hua Bai; Zhi-Jun Wang; Feng Duan; Jin-Xin Fu
Journal:  Chin Med J (Engl)       Date:  2017-08-20       Impact factor: 2.628

6.  Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients.

Authors:  Hayne Cho Park; Chi Weon Kim; Han Ro; Ju-Young Moon; Kook-Hwan Oh; Yonsu Kim; Jung Sang Lee; Yong Hu Yin; Hwan Jun Jae; Jin Wook Chung; Curie Ahn; Young-Hwan Hwang
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

7.  Successfully treated Escherichia coli-induced emphysematous cyst infection with combination of intravenous antibiotics and intracystic antibiotics irrigation in a patient with autosomal dominant polycystic kidney disease.

Authors:  Hyunsuk Kim; Hayne Cho Park; Sunhwa Lee; Jungsil Lee; Chungyun Cho; Dong Ki Kim; Young-Hwan Hwang; Kook-Hwan Oh; Curie Ahn
Journal:  J Korean Med Sci       Date:  2013-06-03       Impact factor: 2.153

8.  Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study.

Authors:  Tatsuya Suwabe; Yoshifumi Ubara; Koki Mise; Masahiro Kawada; Satoshi Hamanoue; Keiichi Sumida; Noriko Hayami; Junichi Hoshino; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Naoki Sawa; Kenmei Takaichi
Journal:  BMC Nephrol       Date:  2013-08-27       Impact factor: 2.388

Review 9.  Introduction to clinical research based on modern epidemiology.

Authors:  Junichi Hoshino
Journal:  Clin Exp Nephrol       Date:  2020-03-24       Impact factor: 2.801

Review 10.  Management of portal hypertension and ascites in polycystic liver disease.

Authors:  Lucas H P Bernts; Joost P H Drenth; Eric T T L Tjwa
Journal:  Liver Int       Date:  2019-09-20       Impact factor: 5.828

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.